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Article Information  ABSTRACT 
Received: 24th July 2018  The main objective of this study was to prepare quick dispersible tablets of drug sumatriptan 
succinate, which can rapidly disintegrate in the saliva using three different superdisintegrants that 
is, sodium starch glycolate, crospovidone, and croscarmallose sodium with taste masking 
polymer beta-cyclodextrin and aspartame as a sweetener. The taste masking of the drug was done 
by mixing it with the polymer beta-cyclodextrin using solvent evaporation method and then 
mixing optimized quantity of aspartame to it. The quick dispersible tablets were prepared by 
direct compression technique using taste masked drug and other formulation excipients. The 
effect of various super disintegrants in three different concentrations has been studied. The 
prepared tablets were evaluated for wetting time, in-vitro disintegration time, strength, and in-
vitro dissolution time. As per the results obtained, it was found that the formulation batch no. 4 
was found to be the best formulation, as the data’s obtained by it was found to be in the required 
range of mouth dissolving tablets. 
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INTRODUCTION 
Tablet is the most popular conventional dosage form for oral 
administration, because of ease of self administration, compact 
in nature, easy to manufacture, and that it can be delivered in 
accurate dose [1].
 
Instead of so many advantages there are 
some disadvantages of solid dosage forms, the main drawback 
is difficulty in swallowing “dysphagia” in pediatric and 
geriatric patients, some other problems that occurs are, fear of 
choking, hand tremors, dysphasia, in young patients due to 
underdeveloped muscular and nervous system, etc., which 
leads to patient incompliance, for this reason, tablets that can 
be rapidly dissolve or disintegrate in the oral cavity are to be 
formulated.
 
Due to this reason, the fast dissolving tablets have 
attracted a great deal of attention in the field of pharmacy [2]. 
United state food and drug administration (FDA), defined fast 
dissolving tablet as “a solid dosage form containing medicinal 
substance or active ingredient which disintegrate rapidly 
usually within a matter of seconds when placed upon the 
tongue” [3]. Orodispersible tablets are also known as mouth 
dissolving tablets, melt-in-mouth tablets, fast dissolving tablets, 
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repimelts, porous tablets, quick dissolving tablets. 
Orodispersible tablets dissolve or disintegrate in the oral cavity 
without the need of water. As orodispersible tablets are, tend to 
be dissolved in mouth the drug will be partially dissolved in the 
taste buds [4]. Thus, the taste inside the mouth becomes critical 
for the patient acceptance. For the bitter or partially bitter 
drugs, taste masking becomes an important criterion for the 
formulation of orodispersible tablets. The orodispersible tablets 
must include taste-masking agent for masking the bitter taste of 
drugs as they are formulated to be dissolved in mouth. The time 
for disintegrating tablets is generally considered less than one 
minute [5].  
Orodispersible dosage forms have several advantages over 
other dosage forms such as; allow high drug loading, ability to 
provide advantages of liquid medication in the form of solid 
preparation, cost-effective, adaptable and amenable to existing 
processing and packaging machinery [6]. Inspite of having so 
many advantages the fast dissolving drug delivery system have 
some limitations, such as, tablets usually have insufficient 
mechanical strength, more susceptible to degradation by 
humidity and temperature, and it is sometimes difficult in 
developing extremely high doses [7]. 
Migraine is a primary episodic headache disorder characterized 
by various combinations of neurological, gastrointestinal, and 
autonomic changes.
 
Migraine is one of the most common 
causes of severe and reoccurring headache.
 
Usual symptoms in 
adults include extreme pain on one or both the sides of the 
head, throbbing in nature, pain in the eye, jaw, face or neck, 
nausea, vomiting, etc.
 
The migraine attack may start with 
premonitory symptoms, following aura and resolution phases. 
Thus, the patients suffering from such disease needs quick 
relief from the severe headache, for this it is required to 
formulate such a dosage form that can provide quick relief 
from such severe condition. Fast dissolving drug delivery 
system is such an approach that may provide the required 
benefits for the treatment of the disease [6]. 
Sumatriptan is an antimigraine drug, it is a 5-HT1B/1D serotonin 
receptor agonist, it has a short half life of approximately 2 
hours, its oral dose is 50- 100 mg. It is absorbed from the 
completely GI tract. It has low oral bioavailability of about 
14%, the reason behind its low bioavailability is first pass 
metabolism. The bioavailability of the drug may increase by 
formulating the drug as fast dissolving tablet. Because the drug 
is taken without water, thus some of its residue may remain in 
the oral cavity from which some part of drug may absorbed 
from oral cavity, pharynx and esophagus leads to reduce the 
first pass metabolism [8]. Sumatriptan is available as 
subcutaneous injection but the problem is that this is painful 
and dosage is not economic and easily available to all patients. 
It is also available as conventional tablet, which has less 
advantage than fast dissolving drug delivery system [8]. The 
main Aim of the research work is to formulate, evaluate and 
optimize the taste masked Quick Dispersible tablets of 
Sumatriptan. The main objective behind formulating such 
dosage form is to provide quick relief from the severe 
conditions of the disease by decreasing the disintegration time 
also increasing the bioavailability of the drug by avoiding first 
pass metabolism. The other conventional dosage form of the 
drug has many disadvantages i.e. patient incompliance which 
includes dysphagia (difficulty in swallowing), for children and 
elderly people, bitter taste of the drug, etc. These drawbacks of 
conventional tablets can be overcome by the fast dissolving 
drug delivery system.  
 
MATERIALS & METHODS 
All materials used in the present research were of analyzed 
grades. Drug Sumatriptan Succinate was obtained from Nosch 
Labs Private Ltd. Hyderabad, polymers Beta-cyclodextrin, 
Sodium Starch Glycolate, Microcrystalline Cellulose, 
Magnesium Stearate, Talc, Sodium Starch Glycolate, and di-
potassium hydrogen phosphate were obtained from SD Fine 
Chem Ltd. Mumbai, Vanillin and Mannitol were obtained from 
Loba Chemicals, Mumbai, Crospovidone was obtained from 
Signet, Mumbai. 
 
Preformulation studies of pure drug 
Identification of drug sample using FTIR 
This was carried out for the identification of the drug sample. 
For this, 10mg of drug sample and 400 mg of KBr were taken 
in mortar and triturated. A small amount of the triturated 
sample was taken and kept onto the sample holder and scanned 
from 4000cm
-1
 to 400cm
-1
 in F.T.I.R. Spectrophotometer. The 
spectra obtained were obtained and interpreted for the 
functional group peaks. 
Determination of melting point 
As per pharmacopoeia range of melting point of Sumatriptan 
Succinate is given between 218˚- 255˚C. The melting point of 
Sumatriptan Succinate was determined by using melting point 
apparatus. For this, take a small amount of drug sample in 
capillary tube which was one sided closed and placed in a 
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melting point apparatus and the temperature at which drug 
melts was noted.  
Solubility analysis 
A semi quantitative determination of the solubility was made 
by adding solvent in small amount to a test tube containing 
fixed quantity of solute or vice-versa. After each addition, the 
system is vigorously shaken and examined visually for any 
undissolved solute particles. 
Preparation of calibration curve in pH 6.8 phosphate buffer 
An accurately weighted amount of Sumatriptan Succinate 
equivalent to 100mg was dissolved in small amount of pH 6.8 
Phosphate Buffer in 100ml volumetric flask and volume made 
up to 100ml with the same pH 6.8 Phosphate Buffer. From this 
stock’s solution, 1ml, 2ml, 3ml, 4ml, 5ml, 6ml, 7ml, 8ml, 9ml 
and 10ml were withdrawn and diluted up to 10ml with the pH 
6.8 Phosphate Buffer in 10ml volumetric flask to get 
concentration of 1µg, 2µg, 3µg, 4µg, 5µg, 6µg, 7µg, 8µg, 9µg 
and 10µg respectively. The absorbance of each solution was 
measured by UV-Visible Spectrophotometer at 226 nm using 
pH 6.8 Phosphate Buffer as blank.  
 
Drug Excipients Interaction Study by FTIR 
To check the compatibility drug and polymer in preparation of 
mouth dissolving tablet of Sumatriptan Succinate, the drug and 
excipients mixture of quantity 10 mg and 400 mg of KBr were 
taken in a mortar and were triturated. A small amount of the 
triturated sample was taken and kept onto the sample holder & 
scanned from 4000 – 400cm-1 in F.T.I.R. Spectrophotometer. 
The spectra obtained were matched with that of the peaks 
obtained from the FTIR study of the pure drug sample and 
interpreted for the interaction of drug and excipients if any. 
 
Preparation of drug and beta-cyclodextrin complex for 
Taste Masking 
Drug cyclodextrin complex was prepared by solvent 
evaporation method, weighed amount of drug was taken with 
different concentrations of beta-cyclodextrin i.e. 1:1, 1:2, 1:3, 
1:4 and 1:5 (Drug: Beta-cyclodextrin, respectively) in separate 
beakers and was dissolved in common solvent i.e. purified 
water. Both the solution mixtures were then mixed together and 
were allowed to evaporate. After evaporation of the solvent a 
powdered mass of drug cyclodextrin complex was found, 
which was then collected as a drug cyclodextrin complex. Also 
three different concentrations of Aspartame were taken i.e. 2%, 
4% and 6% 
Preparation of Sumatriptan Succinate tablets by direct 
compression method 
Tablets of Sumatriptan Succinate were prepared by direct 
compression method. All the formulation ingredients 
mentioned in formulation table were weighed accordingly and 
mixed in a mortar and pestle. This powder blend was then 
allowed to dry for few moments and then again mixed well and 
passed through sieve no 60. Then blend were used for further 
processing 
 
Evaluation of Pre-Compression Characteristics of Powder 
Blend 
Powder blend prepared were evaluated for various rheological 
properties like bulk density, tapped density, Hausner’s ratio, 
angle of repose by using standard procedures. All these 
properties were carried out in triplicate (n=3) and average 
values were reported. 
Bulk density 
Bulk density is determined by placing the powders blend in a 
measuring cylinder and the total volume is noted. The weight 
of powder bed is determined by using digital weighing balance. 
Bulk density is calculated using the following formula
 
Bulk Density = Weight of the powder / Volume of the 
powder 
Tapped density 
Tapped density is determined by taking the dried powders in a 
measuring cylinder and measures the volume of powders after 
100 tapping’s and take weight of the total powders. 
Tapped Density = Weight of the powder / Tapped Volume 
of the powder 
Angle of repose 
Angle of repose was determined by measuring the height and 
radius of the heap of the powder bed. A cylindrical two side 
open tube of 6 cm length is place on graph paper. Powders are 
placed in the tube and slowly removed the tube vertically. With 
the help of scale the height and radius of the heap were 
measure and note.  
   θ= tan-1 h / r 
Where, h = height of heap of granular bed, r = radius of heap of 
granular bed. 
Hausner’s Ratio 
It is expressed in percentage and is expressed by 
H=Dt/Db  
Where Dt is the tapped density of the powder 
Db is the bulk density of the powder.
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Compression of powders into Tablets 
After adding Lubricant (talc) and glidant  (magnesium stearate) 
to the prepared powders, they were compressed into tablets on 
a tablet rotatary compression machine using 10mm diameter, 
flat faced punches  
 
Table 1: Formulation Chart for the preparation of Tablets 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 
Drug-βCD complex 150 150 150 150 150 150 150 150 150 
Sodium starch glycolate 6.25 12.5 18.75 - - - - - - 
Crospovidone - - - 6.25 12.5 18.75 - - - 
Croscarmallose sodium - - - - - - 6.25 12.5 18.75 
Aspartame 15 15 15 15 15 15 15 15 15 
Talc 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
Magnesium Stearate 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
Vanillin 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
Mannitol (filler) 23.75 21.67 19.6 23.75 21.67 19.6 23.75 21.67 19.6 
Microcrystalline cellulose (filler) 47.5 43.33 39.15 47.5 43.33 39.15 47.5 43.33 39.15 
 
Evaluation of compression characteristics of tablets [9,11] 
The prepared tablets were evaluated for their thickness, 
friability, hardness, weight variation and dissolution test by 
using standard procedures.  
Weight variation test 
20 tablets are taken and their weight is determined individually 
and collectively on a digital weighting balance. The average 
weight of one tablet is determined from the collective weight. 
Note more than 2 of the individual weights may deviate from 
the average weight by more than the percentage deviation 
given in the monographs and none should deviate by more than 
twice that percentage given in the monographs. 
Thickness test 
The tablets were evaluated for their thickness using a venirer 
caliper measured in terms of micrometer. Averages of three 
readings were taken and the results were tabulated (n = 3) 
Hardness test 
Prepared tablets were evaluated for their hardness by using 
Monsanto hardness tester. The hardness was measured in terms 
of kg/cm
2
. Triplicate readings were taken and average was 
determined. 
Friability test 
Roche friabilator was used for testing the friability of the 
tablets. For this test, 20 tablets were weighted accurately and 
placed in the friabilator chamber and rotated at 25rpm for a 
period of 4 min. Tablets were again weighted and the 
percentage weight loss was determining by using formula given 
below. 
% Friability = [(W1-W2)100]/W1 
Where, 
W1= Weight of tablet before test 
W2 = Weight of tablet after test. 
Wetting Time 
A piece of tissue paper folded twice was placed in a small Petri 
dish containing 6 ml of purified water, then a tablet was placed 
on the paper and the time required for complete wetting was 
measured. 
Wetting time corresponds to the time taken for the tablet to 
disintegrate when placed gently on the tissue paper in a 
Petridish. Less wetting time indicates more porous tablets. 
In-Vitro Disintegration Time 
 In this Method one tablet was placed in the disintegration 
apparatus  containing 500 ml of distilled water at 37ºC ± 0.5ºC 
and the time required for complete dispersion was determined 
the reading was noted in triplicate and average was calculated. 
In-vitro drug release study 
Drug release study was carried out using USP dissolution rate 
test apparatus (Apparatus II, 50 rpm, 37˚C) for half an hour in 
phosphate buffer pH 6.8. For the first 5 minutes 5ml sample 
was withdrawn in a time interval of 1 minute, and for the next 
25 minutes, the sample was withdrawn in a time interval of 5 
minutes. 5 ml of the sample was withdrawn and diluted with 
the same media up to 10ml, and 5ml of the fresh media was 
poured to the dissolution medium for maintaining the sink 
condition. The samples were analyzed at 226nm using UV–
Spectrophotometer. 
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Kinetic model of drug release  
All the formulation of prepared tablets were subjected to 
invitro release studies these studies were carried out using 
dissolution apparatus, pH 7.2 phosphate buffer the results 
obtaining in vitro release studies were plotted in different 
model of data treatment as follows: 
 Cumulative percent drug released vs. time (zero order rate 
kinetics) 
 Log cumulative percent drug retained vs. time (First Order 
rate Kinetics) 
 Log cumulative percent drug released vs. square root of 
time (Higuchi’s Classical Diffusion Equation) 
 Log of cumulative % release Vs log time (Peppas 
Exponential Equation) 
 
Zero Order Kinetics  
A zero-order release would be predicted by the following 
equation. 
At = A0 – K0t 
Where: 
At = Drug release at time‘t’ 
A0 = Initial drug concentration 
K0 = Zero-order rate constant (hr
-1
). 
When the data was plotted as cumulative percent drug release 
versus time, if the plot was linear then the data obeys zero-
order release kinetics, with a slope equal to K0. 
First Order Kinetics  
A first-order release would be predicted by the following 
equation. 
            
  
     
 
Where: 
C = Amount of drug remained at time‘t’ 
C0 = Initial amount of drug 
K = First-order rate constant (hr
-1
). 
When the data was plotted as log cumulative percent drug 
remaining versus time, yields a straight line indicating that the 
release follows First-order kinetics. The constant ‘K’ can be 
obtained by multiplying 2.303 with slope values. 
 
Higuchi’s Model 
Drug released from the matrix devices by diffusion has been 
described by following Higuchi’s classical diffusion equation. 
   
  
             
 
   
 
Where: 
Q = Amount of drug released at time‘t’ 
D = Diffusion coefficient of the drug in the matrix 
A = Total amount of drug in unit volume of matrix 
CS = The solubility of the drug in the diffusion medium 
ε = Porosity of the matrix 
τ = Tortuosity 
t = Time (hrs) at which ‘Q’ amount of drug is released. 
Equation may be simplified if one assumes that D, CS and A 
are constant. Then equation becomes 
     
When the data was plotted according to new equation i.e., 
cumulative drug released versus square root of time, yields a 
straight line, indicating that the drug was released by diffusion 
mechanism. The slope is equal to ‘K’. 
 
Korsmeyer and Peppas Model  
The release rates from controlled release polymeric matrices 
can be described by the equation proposed by Korsmeyer et al. 
       
Q is the percentage of drug released at time‘t’, K is a kinetic 
constant incorporating structural and geometric characteristics 
of the tablets and ‘n’ is the diffusion exponent indicative of the 
release mechanism. For Fickian release, less than n=0.45 while 
for anomalous (Non-Fickian) transport, n ranges between 0.45 
and 0.89 and for zero order release, more than n = 0.89. 
 
RESULT AND DISCUSSION 
Identification of Sumatriptan Succinate by FTIR 
 
Fig 1:   IR Spectra of pure drug Sumatriptan Succinate 
In the table we found that the peaks obtained by performing 
FTIR of pure drug were found to be in between the range of 
main principle peaks recorded previously as theoretical range, 
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hence this indicates that the drug is pure. These observations 
were found to be in concurrence with the structure of the drug 
molecule. 
Table 2: IR Peak Table with principle peaks of sumatriptan 
succinate 
Functional group of 
Sumatriptan Succinate 
Range of 
Principle Peaks 
Peaks 
Obtained 
N-H of Indole 3369 3358.07 
O=S=O 2964-2775 
2954.95, 
2777.50 
conjugated C=C double bond 1640 1635.64 
O-H bending vibration 1400 1402.25 
Drug Polymer Compatibility Studies: 
To check the compatibility drug and polymer in preparation of 
matrix tablet of Sumatriptan Succinate. The spectra obtained 
from the FT-IR studied at wavelength from 4000cm
-1
 to 400cm
-
1
 are shown fig 2 and the characteristics peaks obtained are 
shown in table 3 [10,12] 
 
Fig 2: IR spectra of prepared Mouth Dissolving Tablets of 
Sumatriptan Succinate mouth dissolving Tablet 
 
Table 3: IR peak table of prepared mouth dissolving tablets 
of sumatriptan succinate  
Functional groups 
Principle 
peaks 
Peaks of  
pure drug  
Peaks of 
formulation 
N-H of Indole 3369 3358.07 3354.21 
O=S=O 
2964-
2775 
2954.95, 
2777.50 
2916.37, 
2775.57 
conjugated C=C 
double bond 
1640 1635.64 1635.64 
O-H bending vibration 1400 1402.25 1394.53 
After performing FTIR of the best formulation of Sumatriptan 
Succinate mouth dissolving tablet it was found that the peaks 
obtained were in between the range of main principle peaks and 
were found to be very near to previously performed FTIR of 
pure drug Sumatriptan Succinate. No major deviation in peaks 
were obtained in IR spectra, hence this indicates that there is no 
interaction between drug and other tablet ingredients.  
Determination of melting point 
Melting point of pure drug was found to be 168°C that was in 
range of 165°- 169°C, actual melting point of Sumatriptan 
Succinate as per pharmacopoeia.  
Solubility analysis 
The pure drug sample of Sumatriptan Succinate was found to 
be freely soluble in water, sparingly soluble in methanol, 
soluble in pH 6.8 pH phosphate buffer, freely soluble in 0.1 N 
HCL. 
Preparation of standard graphs for Sumatriptan Succinate 
Standard graphs for the drug Sumatriptan Succinate was 
performed using pH 6.8 Phosphate buffer. Table shows the 
concentration of Sumatriptan Succinate in pH 6.8 Phosphate 
buffer and its respective absorbance. The figure shows the 
calibration curves of Sumatriptan Succinate performed. 
Table 4: Data for standard curve of Sumatriptan Succinate  
Concentration (µg/ml) Absorbance (226nm) 
1 0.13298 
2 0.25839 
3 0.37398 
4 0.52615 
5 0.62971 
6 0.75891 
7 0.89197 
Fig 3: Standard calibration curve of sumatriptan succinate 
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Characterization of Sumatriptan Succinate tablets 
Evaluation of pre-compression characteristics of powder 
blend 
The Pre-compression evaluations of prepared powders were 
shown below. The powders were evaluated for bulk density, 
tapped density, Hausner’s ratio and angle of repose and 
consistency in data obtained as indicated by their standard 
deviation values shown in table. 
Table 5: Data of pre-compression characteristics of powder 
blend  
Batch Bulk 
Density 
Tapped 
Density 
Hausner’s 
ratio 
Angle of 
repose () 
F1 0.416±0.003 0.563±0.002 1.35±0.017 21.73±0.20 
F2 0.461±0.002 0.581±0.003 1.25±0.013 34.13±0.20 
F3 0.452±0.002 0.571±0.004 1.26±0.008 35.03±0.20 
F4 0.414±0.003 0.6±0.002 1.44±0.005 32.39±0.08 
F5 0.451±0.002 0.583±0.002 1.29±0.012 29.29±0.07 
F6 0.423±0.003 0.545±0.003 1.28±0.014 30.58±0.02 
F7 0.490±0.001 0.585±0.002 1.19±0.007 30.87±0.35 
F8 0.477±0.003 0.559±0.002 1.17±0.012 31.36±0.14 
F9 0.472±0.002 0.574±0.001 1.21±0.008 33.27±0.31 
Pre-compression characteristics were investigated for all 9 
formulations and the study showed following results. Bulk 
density and tapped density of different formulations were 
calculated. The result of bulk density range from 0.414 to 0.477 
and tapped density from 0.545 to 0.6. Hausner’s ratio was 
found to be in between 1.17 to 1.35. Angle of repose showed 
good to excellent flow properties of the powdered blend. F1, 
F5, F6 and F7 were found to be having excellent flow 
properties. 
 
Evaluation of mouth dissolving tablet of Sumatriptan 
Succinate 
The evaluations of prepared Mouth Dissolving tablet were 
shown below. The tablets were evaluated for thickness, 
hardness, Weight variation, friability, wetting time, in-vitro 
disintegration time, dissolution study and consistency in data 
obtained as indicated by their standard deviation values, shown 
in table No. 4. All prepared batches were found to have small 
variations in between thickness of all formulation but in a 
particular formulation there was no such variation. The 
thickness of all formulation was found in between 3.1±0 to 
3.5±0 mm.  The hardness of the compressed tablets was 
determined by using hardness tester (Monsanto), it was found 
that the tablets prepared were of adequate strength. Hardness of 
tablet of all formulations was found in between the range of 
3.7±0.05 kg/cm
2
 and 4.2±0.49 kg/cm
2
. The hardness of all 
formulation showed variation because of formulation 
combination and powder properties. The friability of all 
formulation was in the range of 0.32 % to .85%. All 
formulations were found to be under standard limit i.e. less 
than 1%, hence passed the test for friability. The weight 
variation of all formulation was in the range of 250.3±1.38 to 
250.85±1.26. The weight variation test was performed 
according to the procedure in the pharmacopoeia. In the weight 
variation test, pharmacopoeial limit is 7.5%. The individual 
deviation of all the tablets formulation was found to be within 
the limit and hence passed the test for uniformity of weight. 
The wetting time and disintegration of the formulation F4 was 
found to be least as compared to other formulations. 
 
Table 6: Data of compressed mouth dissolving tablets of 
sumatriptan succinate 
Formulation  
No. 
Thickness 
(mm) 
Hardness 
(Kg/cm
2
) 
Friability 
(%) 
F1 3.13±0.05 4.1±0.17 0.74±0.01 
F2 3.2±0 3.9±0.05 0.32±0.005 
F3 3.1±0 3.9±0.11 0.65±0.02 
F4 3.5±0 3.8±0.11 0.43±0.01 
F5 3.3±0 4.2±0.49 0.77±0.005 
F6 3.2±0 3.7±0.05 0.72±0.02 
F7 3.1±0 4±0 0.85±0.03 
F8 3.1±0 3.9±0.01 0.76±0.02 
F9 3.13±0.05 3.9±0.011 0.74±0.03 
Table 7: Data of compressed mouth dissolving tablets of 
sumatriptan succinate 
Batch 
Weight 
variation (%) 
Wetting time 
(seconds) 
Disintegration 
time (seconds) 
F1 Passed 42.63±.18 50.66±2.08 
F2 Passed 46.16±1.6 65.66±3.51 
F3 Passed 51±2 65.33±2.88 
F4 Passed 38.16±1.25 41±3 
F5 Passed 52.33±3.21 35.66±3.51 
F6 Passed 78.66±2.08 53.23±3.34 
F7 Passed 75.33±3.05 68.33±3.21 
F8 Passed 54±5.29 100.33±1.5 
F9 Passed 92±2.64 62.33±2.51 
The values of pre-compression and post compression 
parameters evaluated were within prescribed limits as well as 
indicated a good free flowing property and post compression 
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parameters like hardness, friability, in-vitro disintegration time, 
thickness, wetting time, were also found to be within the limits. 
 
Fig 4: In vitro drug release Graph 
To know the mechanism of the drug release from these 
formulations, the data were fixed in kinetic model i.e. zero 
order, first order, higuchi model, Korsmeyer Peppas model. 
The release rate kinetic data for all the other equation are 
shown in table. When the data was plotted according to the 
kinetic model, the formulation showed a fair linearity. The 
model that best fits the release data is selected based on the 
correlation coefficient (r
2
) value in various models. The model 
that gives higher value of ‘r’ is considered to be the best fit of 
the release data. The value of n (diffusion constant) for all the 
formulations were found to be less than 0.45, this indicates that 
the formulations followed Fickian model for drug release.  
 
CONCLUSION 
It was concluded that mouth dissolving tablets of Sumatriptan 
Succinate can be successfully prepared by direct compression 
techniques using various superdisintegrants for the better 
patient compliance and effective therapy. Also the bitter drug 
can be easily formulated as mouth dissolving tablets by 
masking their taste using beta-cyclodextrin as taste masking 
polymer and aspartame as a sweetener without affecting any 
parameters of the tablet. It was also found that the 
superdisintegrants are effective at an optimum concentration, 
on increasing their concentration above their optimum 
concentration or mixing with other superdisintegrants it starts 
decreasing its effect. 
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